HUNTINGTON, N.Y., May 22, 2024
/PRNewswire/ -- Sen-Jam Pharmaceutical, a leading innovator in the
development of therapeutics for age-related diseases, is pleased to
announce the upcoming completion of the clinical trial for its
groundbreaking therapeutic, SJP-002C, in July 2024. SJP-002C targets Upper Respiratory
Infections (URIs), including COVID-19, and is poised to
revolutionize the treatment landscape by providing a radically
safe, potent, and widely accessible solution to a global market in
dire need of effective options.
The global pandemic has highlighted the inadequacies of current
treatments for URIs and COVID-19. Existing therapies often come
with significant side effects, high costs, and limited
accessibility, leaving millions of patients without adequate care.
The market is ripe for a disruptor, and SJP-002C is positioned to
fill this critical gap.
"We are thrilled to be nearing the completion of our clinical
trial for SJP-002C," said Jim
Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical.
"We believe the market is missing an oral anti-inflammatory to
quell symptoms and avoid hospitalizations; which are reported to be
between $51,389 to $78,569, depending on factors such as age and
insurance coverage."
SJP-002C hopes to demonstrate significant efficacy in reducing
inflammation in patients with COVID-19 during its Phase 2 clinical
trial, conducted in collaboration with principal investigators Dr.
Ashley St. John and Dr. Alexander
Limkakeng from Duke University. A
preliminary in vitro study showed a significant reduction in viral
load as well as reduction of symptom severity and duration
resulting from the innovative combination of two anti-inflammatory
agents.
With patents filed in 15 countries and a patented streamlined
manufacturing process developed in partnership with KVK Tech,
SJP-002C is well-positioned for rapid global deployment upon
regulatory approval. By leveraging the 505(b)(2) pathway, Sen-Jam
Pharmaceutical anticipates an expedited approval process, bringing
this much-needed treatment to patients as quickly as possible.
Through KVK-Tech the company has completed the formulation and CMC
(Chemistry, Manufacturing, and Controls) work, produced GMP (Good
Manufacturing Practice) product, and is currently producing FDA
submission batches. These factors demonstrate that the therapeutic
is not only clinically viable but also manufacturable at scale,
which reduces risk and adds substantial value.
The market opportunity for SJP-002C is substantial, with the
global respiratory infection market valued at $35 billion in 2023 and the COVID-19 therapeutics
market alone worth $16 billion. As a
cost-effective and highly efficacious treatment, SJP-002C has the
potential to capture a significant share of these markets while
providing accessible care to patients in need.
"We believe that SJP-002C has the potential to transform the
treatment of Upper Respiratory Infections and COVID-19,"
Iversen continued. "We are committed to bringing this innovative
therapeutic to patients worldwide because we believe runaway
inflammation is the root cause, not the consequence, of
debilitation with these infections. The global healthcare community
needs to focus more precisely on acute and chronic inflammation –
especially neuroinflammation – to truly transform health and
preserve lives."
Dr. Ashley St. John, pioneering
Immunologist with Duke-National University of
Singapore agrees. "With many conditions that involve
runaway inflammation, what we need therapeutically are more
sophisticated methods to take the foot off that inflammatory gas
pedal." Dr. St. John most recently was awarded a
prestigious National Research Foundation Award for her
ground-breaking work in immunology.
Sen-Jam Pharmaceutical is actively seeking retail investors,
investment partners and strategic collaborations to support the
Phase 3 clinical trials and global licensing for commercialization
of SJP-002C. They also are advancing ten other novel assets with
three of them at or approaching Phase 2 clinical trial work. Their
platform aims to revolutionize the way the world treats
inflammation and the way the pharmaceutical industry treats
humanity.
About Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is a clinical-stage biopharmaceutical
company dedicated to developing innovative therapeutics for
age-related diseases by repurposing small molecules through the
505(b)(2) pathway. With a focus on addressing significant unmet
medical needs and with a platform revolutionizing the market with
next generation anti-inflammatories, Sen-Jam Pharmaceutical is
committed to improving patient lives through safe, effective, and
accessible treatments.
CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
378154@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-announces-upcoming-completion-of-sjp-002c-clinical-trial-offering-hope-for-a-safe-potent-and-globally-affordable-treatment-for-upper-respiratory-infections-and-covid-19-302153274.html
SOURCE Sen-Jam Pharmaceutical